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Abstract
ABCG2 is an efflux transporter conferring multidrug resistance (MDR) on cancer cells. However, the initial molecular
events leading to its up-regulation in MDR tumor cells are poorly understood. Herein, we explored the impact of drug
treatment on the methylation status of the ABCG2 promoter and consequent reactivation of ABCG2 gene expression
in parental tumor cell lines and their MDR sublines. We demonstrate that ABCG2 promoter methylation is common in
T-cell acute lymphoblastic leukemia (T-ALL) lines, also present in primary T-ALL lymphoblast specimens. Furthermore,
drug selection with sulfasalazine and topotecan induced a complete demethylation of the ABCG2 promoter in the
T-ALL and ovarian carcinoma model cell lines CCRF-CEM and IGROV1, respectively. This resulted in a dramatic induc-
tion of ABCG2 messenger RNA levels (235- and 743-fold, respectively) and consequent acquisition of an ABCG2-
dependent MDR phenotype. Quantitative genomic polymerase chain reaction and ABCG2 promoter-luciferase
reporter assay did not reveal ABCG2 gene amplification or differential transcriptional trans-activation, which could
account for ABCG2 up-regulation in these MDR cells. Remarkably, mimicking cytotoxic bolus drug treatment through
12- to 24-hour pulse exposure of ABCG2-silenced leukemia cells, to clinically relevant concentrations of the chemo-
therapeutic agents daunorubicin and mitoxantrone, resulted in a marked transcriptional up-regulation of ABCG2. Our
findings establish that antitumor drug–induced epigenetic reactivation of ABCG2 gene expression in cancer cells is an
early molecular event leading to MDR. These findings have important implications for the emergence, clonal selection,
and expansion of malignant cells with the MDR phenotype during chemotherapy.
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Introduction
Despite the profound impact that novel treatment strategies may have on
some malignancies, chemotherapy continues to be the standard of care
in most human cancers. In this respect, multidrug resistance (MDR) re-
mains a major impediment toward curative cancer chemotherapy [1].
The ATP-binding cassette (ABC) superfamily of human membrane
transporters consists of 49 members mediating a broad spectrum of
physiological functions [2,3]. Moreover, the overexpression of several
ABC transporters, including ABCB1 (MDR1/Pgp), members of the
ABCC group (MRPs) and ABCG2 (BCRP/MXR), results in ATP-
driven efflux of antitumor drugs from cancer cells, thereby leading to
decreased intracellular drug accumulation and consequent MDR [4–
8]. These drug efflux pumps display a high-transport capacity toward
a partially overlapping array of structurally dissimilar cytotoxic agents,
thereby creating an active cellular defense network against a multitude
of chemotherapeutic drugs [9–11].
DNA methylation within CpG islands is a well-established mecha-
nism mediating epigenetic silencing of gene expression [12]. This pro-
cess is a prerequisite in vertebrate development and in tissue-specific
gene expression [13,14]. CpG island methylation can cause repres-
sion of gene expression either directly through steric hindrance of
methyl-CpGs with transcription factors such as E2F or CREB [15,16]
Abbreviations: ABC, ATP-binding cassette; Act D, actinomycin D; ALL, acute lympho-
blastic leukemia; COBRA, combined bisulfite restriction analysis; DNMT, DNAmethyl-
transferase; DNR, daunorubicin; Dox, doxorubicin; FTC, fumitremorgin C; HDACi,
histone deacetylase inhibitor; MDR, multidrug resistance; MX, mitoxantrone; SSZ,
sulfasalazine; TSA, trichostatin A; QPCR, quantitative polymerase chain reaction;
5-Aza-dC, 5-Aza-2′-deoxycytidine
Address all correspondence to: Yehuda G. Assaraf, The Fred Wyszkowski Cancer Re-
search Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa
32000, Israel. E-mail: assaraf@tx.technion.ac.il
1This work was supported by a grant from The Fred Wyszkowski Cancer Research
Fund (to Y.G.A.).
2This article refers to supplementary materials, which are designated by Figures W1
and W2 and are available online at www.neoplasia.com.
Received 2 August 2009; Revised 11 September 2009; Accepted 14 September 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.91314
www.neoplasia.com
Volume 11 Number 12 December 2009 pp. 1359–1370 1359
or indirectly through recruitment of methyl-binding proteins, which
actively repress transcription [17]. Further association of methyl-binding
proteins with chromatin-modifying proteins produces a complementary
repressive heterochromatin environment [18,19]. Simultaneous genome-
wide hypomethylation and gene-specific hypermethylation events under-
lie cancer etiology and may account for cancer hallmarks such as global
genomic instability and tumor-suppressor gene silencing, respectively
[20–22]. CpG island hypermethylation and consequent gene silencing
in cancer was found to be mediated by the deregulation of DNAmethyl-
transferases (DNMTs), particularly DNMT1 and DNMT3a/b, which
are responsible for maintenance and de novo methylation, respectively
[23]. Thus, reactivation of aberrantly silenced tumor-suppressor genes
through DNMT inhibition has recently become a relevant molecular
target for therapy, currently used for treatment of hematological malig-
nancies [24–26].
Several mechanisms of drug-induced up-regulation of gene expres-
sion have been proposed for the extensively studied MDR transporter
ABCB1 (P-glycoprotein,MDR1), ranging fromkaryotypic abnormalities
to altered transactivation [27–29]. El-Osta et al. [30] have described
epigenetic alterations including promoter demethylation, leading to up-
regulation of ABCB1 in adriamycin-selected CCRF-CEM cells (CEM-
A7R). Similar results were consistently obtained with vincristine-selected
KB3-1 cells [31]. In a following study, Baker et al. [32] demonstrated the
direct epigenetic up-regulation of themdr1 gene within a single cell cycle,
in antiapoptotic, bcl2-transfected CCRF-CEM-bcl2 cells, occurring in
response to chemotherapeutic drug exposure. Recently, To et al. [33] have
shown an active CpG island within the proximal ABCG2 promoter re-
gion, thereby facilitating its transcriptional silencing in aberrantlymethyl-
ated renal cell carcinoma lines. A follow-up report by Turner et al. [34]
demonstrated that ABCG2 expression in multiple myeloma patients is
regulated in part by promoter methylation. Subsequent studies have
begun to elucidate the major role that epigenetics play in the transcrip-
tional regulation of the abcg2 gene. Specifically, two recent reports
documented the impact of single-step and long-term anticancer drug
selection on the association of chromatin-remodeling proteins to the
abcg2 locus and concomitant ABCG2 expression, in several carcinoma
cell lines [35,36]. However, the role and dynamics of ABCG2 promoter
methylation under anticancer drug exposure have not been addressed,
hence leaving a crucial part of the early epigenetic machinery governing
ABCG2 transcription poorly understood. Toward this end, we here
studied the methylation status of the ABCG2 promoter in different
malignant cell lines and their ABCG2-overexpressing MDR counter-
parts. We provide the first evidence that anticancer drug selection of
cell lines harboring a transcriptionally silenced ABCG2 results in the
complete loss of abcg2 promoter methylation, ultimately leading to a
marked transcriptional up-regulation and consequent MDR. Moreover,
this transcriptional up-regulation of epigenetically silenced genes is ob-
served as early as 12 hours after drug exposure, hence indicating that
drug-induced epigenetic up-regulation of ABCG2 is an upstream event
leading ABCG2-mediated MDR.
Materials and Methods
Drugs and Chemicals
Daunorubicin (DNR), doxorubicin (Dox), mitoxantrone (MX), sul-
fasalazine (SSZ), Taxol, 5-Aza-2′-deoxycytidine (5-Aza-dC), actino-
mycin D (Act D), trichostatin A (TSA), and zebularine (ZEB) were
obtained from Sigma Chemical Co (St Louis, MO). Fumitremorgin C
(FTC), topotecan (Topo), and SN-38 were kindly provided by Dr. S. E.
Bates, National Cancer Institute, Bethesda, MD.
Tissue Culture
Human malignant cell lines, namely ovarian carcinoma IGROV1,
MCF7 breast cancer cells, A549 non–small cell lung cancer cells,
T-cell leukemia lines—Jurkat, CCRF-CEM, andMOLT4—and erythro-
leukemia K562 cells, were grown either under monolayer conditions
(attached cell lines) or up to a maximal density of 106 cells/ml (for
leukemic cell lines), in RPMI-1640 medium (Invitrogen Gibco, Carls-
bad, CA) supplemented with 10% fetal calf serum, 2 mM glutamine,
100 μg/ml penicillin, and 100 μg/ml streptomycin (Biological Industries,
Beth-Haemek, Israel) in a humid atmosphere of 5% carbon dioxide.
Matches drug-resistant IGROV1/T8, –MX3, MCF7/MR, –FLV1000,
A549/K1.5, and CCRF–CEM/SSZ1.5, –2.5 cells, harboring ABCG2
overexpression, weremaintained in the previouslymentioned conditions,
under pulse or continuous drug selection, as described previously [37–
40]. IGROV1 and its drug-resistant sublines were generously provided
by Dr. Jan H. M. Schellens, Department of Medical Oncology, The
Netherlands Cancer Institute, Amsterdam, the Netherlands, and CCRF-
CEMand its SSZ-resistant sublines were a gift fromDr.Gerrit Jansen,De-
partment of Rheumatology, VU University Medical Center, Amsterdam,
the Netherlands. For cytotoxicity experiments, cells were grown in drug-
free medium for at least 1 week before the experiments.
Drug Treatment with Zebularine, 5-Aza-dC, or TSA
IGROV1, CCRF-CEM cells, and their MDR sublines were grown
in medium containing 2 μM 5-Aza-dC (Sigma) for 72 hours, and the
5-Aza-dC–containing medium was replaced every 24 hours. TSA or
Act D (Sigma) were added to the appropriate cultures at a concentra-
tion of 75 ng/ml or 0.5 μg/ml, respectively, and incubated for the
final 20 hours. Alternatively, sequential treatment of CCRF-CEM
cells with 50 μM zebularine was carried out for 30 days as previously
described [41]. Cell viability was assessed using trypan blue staining,
and drug concentrations were optimized to achieve maximal transcrip-
tional change while minimally affecting cell viability. After treatment,
genomic DNA or RNA were isolated, and bisulfite conversion or re-
verse transcription–polymerase chain reaction was performed, respec-
tively, as described later.
Anticancer Drug Treatment
CCRF-CEM, Jurkat, and K562 cells were grown in medium con-
taining 0.01 to 15 μMMX, DNR, or Dox; 0.001 to 2 mM SSZ; 0.01
to 10 μM topotecan; or 0.001 to 1 μM SN-38. Drug concentration
range was calibrated to span the reported drug concentration required
to inhibit cell growth by 50% of the different drugs. Cells were har-
vested at variable time points up to 48 hours, and RNAwas isolated as de-
scribed later. Concurrent addition of Act D (0.5 μg/ml) or FTC (5 μM)
to the cell culture was carried out at the optimal (ABCG2-inducing) drug
concentration for each drug at 20-hour incubations. Cell death was as-
sessed using trypan blue.
Cytotoxicity Assay
ParentalCCRF-CEMcells, their SSZ-resistant subline, and zebularine-
treated cells were seeded in 96-well plates (3 × 104 cells per well) in
growth medium (100 μl per well) containing various concentrations
of MX or SSZ for 72 hours at 37°C in the presence or absence of the
specific ABCG2 transport inhibitor FTC. Viable cell numbers were de-
termined using a hemocytometer after trypan blue staining. The 50%
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inhibition of cell growth was calculated relative to untreated controls.
Results presented are means of at least three independent experiments.
RNA Extraction and Quantification of Gene Expression by
Real-time PCR
RNA extraction and complementary DNA synthesis were carried out
as previously described [37]. The levels of ABCG2, ABCB1, ABCC1,
and PCFT gene expression were determined using a quantitative real-
time PCR method as previously described [37]. Expression levels were
normalized using the β2-MICROGLOBULIN (B2M ) gene as an in-
ternal control. QPCR primers (Table 1) were obtained from Harvard
Primer Bank (http://pga.mgh.harvard.edu/primerbank/index.html).
Results represent means ± SD of three independent experiments.
Isolation of Genomic DNA and Bisulfite Conversion of DNA
Genomic DNA was isolated using The DNeasy Blood & Tissue Kit
(QIAGEN, Valencia, CA) followed by bisulfite conversion of 2 μg of
genomic DNA using the EpiTect Bisulfite Kit (QIAGEN) according
to the instructions of the manufacturer.
DNA Methylation Analysis
The methylation status of abcg2, mdr1, and pcft promoter was
examined using combined bisulfite restriction analysis (COBRA) as
well as bisulfite DNA sequencing as described previously [14]. Sodium
bisulfite–treated DNA was amplified in two subsequent rounds using
primers specifically designed for this purpose (Table 1); some primers
were designed using the Methyl Primer Express software v1.0 (Applied
Biosystems, Foster City, CA) and others were obtained from previ-
ous reports [14,33,42]. COBRA restriction used BstUI and Taq1α re-
striction enzymes for a 200-fold overdigestion period on abcg2 and
pcft, and mdr1 bisulfite converted PCR fragments, respectfully, ac-
cording to the manufacturer’s instructions (New England Biolabs,
Ipswich, MA).
In Vitro Methylation
In vitro methylation was performed using CpG methyltransferases
(M.SssI) according to the instructions of the manufacturer (New
England Biolabs, Ipswich, MA), whereas a mock assay was performed
at the same conditions without the enzyme. After the assay, plasmids were
purified using theWizard SVGel and PCRClean-up kit according to the
instructions of themanufacturer (Promega,Madison,WI), and themeth-
ylation percentage was evaluated using the methylation-sensitive restric-
tion enzymes SalI and NotI present on the pGl3 plasmid.
Transient Transfections with pGL3-abcg2 Promoter
Expression Vectors and Luciferase Reporter Gene Assay
For the luciferase reporter assay, IGROV1 and IGROV1/T8 cells
were grown in 24-mm dishes (3 × 104 cells per well) for 24 hours, after
which cells were transiently cotransfected with either the pGL3-abcg2
constructs (generously provided by Dr. Douglas D. Ross) [43], pGL3-
Basic empty vector, or the in vitro–methylated vectors described, along
with the extensively used pROL control plasmid (Renilla luciferase),
using the jetPEI transfection reagent (Polyplus-transfection; Genesee
Scientific, San Diego, CA) according to the instructions of the man-
ufacturer. Twenty-four hours after transient transfection, cells were
harvested and tested for luciferase and Renilla activities using the
Dual-Luciferase Reporter Assay System (Promega) as described in the
manufacturer’s protocol. Results presented were obtained from at least
three independent experiments performed in duplicate cultures.
Healthy Donor T-cell and T-Acute Lymphoblastic Leukemia
Lymphoblast Specimens
Analysis of ABCG2 promoter methylation status in T-cell lympho-
blasts was performed on stored genomic DNA samples previously
obtained from adult T-cell acute lymphoblastic leukemia (T-ALL) pa-
tients who were treated according to the UKALL12/ECOG 2993 proto-
col [44] at the Department of Hematology, Rambam Medical Center.
The samples were previously derived as part of the routine clinical man-
agement and were used in the current study after receiving approval from
the local institutional review board (study no. 2902) at the Rambam
Medical Center and informed consent in accordance with the Declara-
tion of Helsinki. Percent purity of peripheral T-ALL lymphoblasts for
all patient samples tested was greater than 90%. For genomic DNA ex-
traction, lymphoblasts were isolated from patients’ peripheral blood by a
Table 1. Summarizing Table of Primers Used in This Study.
Genomic PCR Primers for Bisulfite-Treated DNA
Fragment Sense Primer Antisense Primer Length (bp) Tm (°C)
ABCG2 (A) 5′-TTTGTGATTGGGTAATTTGTG-3′ 5′-TCCCTCAAAACTAAAATCACCCTA-3′ 221 53
ABCG2 (B)* 5′-GGAGTGTTTGGTTTGTTTTTG-3′ 5′-CAATAACCCCTCCCCAA-3′ 223 52
PCFT† 5′-TTTTTGTTATTTGTGGTGTGTT-3′ 5′-CAAAATTAACCAAAAAAACCA-3′ 414 56
ABCB1‡ 5′-GGAAGTTAGAATATTTTTTTTGGAAAT-3′ 5′-ACCTCTACTTCTTTAAACTTAAAAAAACC-3′ 223 48
Primers for Quantitative Real-time PCR
Name Sense Primer Antisense Primer Length (bp) Tm (°C)
ABCG2§ 5′-CCCGCGACAGCTTCCAATGA-3′ 5′-GGCGTTGAGACCAGGTTTCA-3′ 171 60
ABCB1¶ 5′-GTGGTGGGAACTTTGGCTG-3′ 5′-TACCTGGTCATGTCTTCCTCC-3′ 188 60
ABCC1¶ 5′-GAGGAACCATATTACAGGTCCGT-3′ 5′-AGGGGATCATCGAAGAAGTAAAT-3′ 188 60
PCFT† 5′-CACTCTACCCAGCCACTCTGAAC-3′ 5′-GATCAGCCTTTTCCAGCATCC-3′ 109 60
B2M† 5′-GGCTATCCAGCGTACTCCAAA-3′ 5′-CGGCAGGCATACTCATCTTTTT-3′ 246 60
*To et al. [33].
†Gonen et al. [14].
‡Lee et al. [42].
§Bram et al. [37].
¶Harvard Primer Bank (http://pga.mgh.harvard.edu/primerbank/index.html).
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standard Ficoll-Hypaque (Sigma) gradient density centrifugation. In ad-
dition, healthy volunteers’ primary T cells were isolated using the Rosette
Human T-Cell Enrichment kit (StemCell Technologies, Vancouver,
British Columbia, Canada), according to the manufacturer’s instructions.
Total genomic DNA was purified using The DNeasy Blood & Tissue
Kit (QIAGEN) according to the instructions of the manufacturer.
Statistical Analyses
We used a 1-tailed nonpaired Student’s t-test to examine the signifi-
cance of the difference between two populations for a certain variable.
A difference was considered significant if the P value obtained was less
than .05.
Results
ABCG2 Is Transcriptionally Upregulated in MDR Tumor
Cell Lines
Real-time PCR analysis revealed a substantial variability in ABCG2
gene expression in tumor cell lines of epithelial and hematological ori-
gins; furthermore, a marked transcriptional up-regulation of ABCG2
was observed in their drug-selected counterparts (Figure 1, black bars).
This up-regulation resulted in a consistent plasma membrane over-
expression of functional ABCG2 and a consequent MDR phenotype
[37–40]. Remarkably, when comparing the extent of ABCG2 over-
expression (expressed as fold difference) in these ABCG2-overexpressing
MDR cells, a differential pattern of up-regulation was apparent; the
MDR cell lines A549/K1.5, MCF7/MR, and MCF7/FLV1000, in
which ABCG2 overexpression was associated with gene amplification
([37]; see Supplementary Data), displayed the highest absolute levels
of ABCG2 messenger RNA (mRNA; Figure 1, black bars). Conversely,
the maximal fold increase in ABCG2 mRNA levels relative to parental
cells was found in the MDR sublines CCRF-CEM/SSZ2.5 and
IGROV1/T8 (Figure 1, gray bars) and may be attributed to the ex-
tremely low basal ABCG2 mRNA levels observed in parental IGROV1
andCCRF-CEMcells (Figure 1, black bars). Interestingly, ABCG2 over-
expression in these MDR cell lines was not due to genomic amplification
or differential transcriptional transactivation (see Supplementary Data).
The ABCG2 Promoter Undergoes Demethylation in MDR Cell
Lines Lacking ABCG2 Gene Amplification
Recently it was shown that the abcg2 promoter undergoes CpG
methylation in the renal carcinoma cell lines UOK121 and UOK143,
thereby resulting in its transcriptional silencing [33]. We therefore
examined the possibility that the extremely low levels of ABCG2 tran-
scripts in human T-cell leukemia CCRF-CEM and ovarian cancer
IGROV1 cells are due to transcriptional silencing of the abcg2 gene
through promoter methylation. Furthermore, the lack of abcg2 gene
amplification or transactivation in their moderately ABCG2-expressing
MDR counterparts, suggested the possibility that the dramatic up-
regulation of ABCG2 in these drug-resistant cell lines may be due to
the loss of transcriptional silencing of this gene. This hypothesis was
tested using COBRA methodology on a 223-bp fragment of the re-
ported CpG island of the ABCG2 promoter (termed fragment B), di-
gested with BstUI. Indeed, parental ABCG2 mRNA levels inversely
correlated with the methylation status of the ABCG2 promoter; ac-
cordingly, A549 and MCF7 cells, which exhibited relatively high basal
levels of ABCG2 mRNA, were devoid of ABCG2 promoter methyla-
tion (Figure 2A). In contrast, both CCRF-CEM and IGROV1 cells
Figure 1. ABCG2 mRNA levels in paired parental and MDR tumor cell lines assessed by QPCR. ABCG2 mRNA levels are expressed as
fold of expression relative to the basal transcript levels of CCRF-CEM cells (black bars) or as fold of expression of the MDR sublines over
their matched parental cells (gray bars).
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displayed high levels of promoter methylation, with greater than 87%
and greater than 50% of the ABCG2 genes being methylated, respec-
tively (Figure 2A). Remarkably, inspection of the ABCG2 CpG island
in the corresponding MDR sublines CCRF-CEM/SSZ, IGROV1/T8,
and IGROV1/MX3 revealed a prominent promoter demethylation (Fig-
ure 2B). These results were further corroborated using direct bisulfite
sequencing of a 386-bp fragment (ranging from −380 to +6 relative
to the transcription initiation site) [43] previously reported to be a func-
tional CpG island that undergoes a dense methylation in the ABCG2
promoter (Figure 2C) [33,43].
Figure 2. Quantitative determination of promoter methylation status in parental and MDR cell lines assessed by COBRA and direct bisulfite
sequencing. Methylation levels were assessed using a PCR-amplified 223-bp fragment of bisulfite-converted genomic DNA from within the
CpG island of the abcg2 promoter of parental A549, MCF7, CCRF-CEM, and IGROV1 cells (A) or their corresponding A549/K1.5, MCF7/MR/
FLV1000, CCRF-CEM/SSZ1.5/2.5, and IGROV1/T8/MX3 MDR cells (B). In addition, two consecutive fragments (termed A and B) from the
abcg2 promoter’s CpG island were subjected to direct bisulfite sequencing (C). Schematic representation of the sequenced genomic frag-
ments including all CpG sites (line representation) is displayed (top). Eight representative clones from parental CCRF-CEM and IGROV1 cells
and their MDR CCRF-CEM/SSZ1.5/2.5 and IGROV1/T8 sublines are presented in dot display (black dot represents a methylated CpG). Also,
the promoter methylation status of the pcft and mdr1 genes in parental CCRF-CEM cells and their MDR CCRF-CEM/SSZ2.5 counterparts
were assessed using a 414- and 223-bp PCR-amplified fragment of bisulfite-converted genomic DNA from within their CpG island, respec-
tively (D). PCR fragments were subjected to 200-fold BstUI (abcg2 and pcft) or TaqIα (mdr1) overdigestion and then compared to various
dilutions of the uncut DNA.
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ABCG2 Demethylation in Nongenomically Amplified MDR
Cell Lines Is Not Due to Global Demethylation
Drug-induced DNA demethylation is known to be either global
or site-specific [25,30,45]. Promoter methylation status of ABCB1
(MDR1/P-glycoprotein) and proton-coupled folate transporter (PCFT/
SLC46A1), the promoters of which were reported to be methylated in
CCRF-CEM cells [14,46], were evaluated in conjunction with their
MDR subline CCRF-CEM/SSZ2.5. As evident from the COBRA
results depicted in Figure 2D, the hypermethylation pattern of both
the mdr1 and pcft promoters observed in parental CCRF-CEM
cells remained intact in CCRF-CEM/SSZ2.5 cells, suggesting that the
marked demethylation of the abcg2 locus under SSZ drug exposure
was presumably a result of a site-specific demethylation event and not
part of a global demethylation process (Figure 2D).
Treatment with Demethylating Agents Results in ABCG2
Promoter Demethylation and Consequent Restoration of
Gene Expression
The high correlation between abcg2 promoter methylation and lack
of gene expression prompted us to further explore the role of epigenetics
inABCG2 gene expression using these ABCG2-methylatedMDR tumor
cell lines. Previous reports demonstrated that treatment with the de-
methylating agent 5-Aza-dC and the histone deacetylase inhibitor
(HDACi) depsipeptide, which induces histone acetylation, resulted
in restoration of ABCG2 gene expression in promoter-silenced tumor
cell lines [33,36]. We thus explored the responsiveness of IGROV1
and CCRF-CEM cells harboring a methylated abcg2 promoter,
to 5-Aza-dC and TSA; as evident from Figure 3, treatment with
5-Aza-dC resulted in an approximately 9- to 11-fold increase in
ABCG2 transcript levels, relative to untreated cells (P = .006 and P =
.004, respectively; Figure 3, A and B). A further increase in ABCG2
gene reactivation in CCRF-CEM and IGROV1 cells was obtained when
combining both treatments with 5-Aza-dC and the HDACi, TSA
(P = .03 and P = .02, respectively; Figure 3, A and B). However, neither
5-Aza-dC alone nor its combination with TSA induced a significant
alteration in ABCG2 gene expression in the corresponding MDR cell
lines CCRF-CEM/SSZ2.5 and IGROV1/T8 (P > .21; Figure 3, C
and D), which initially displayed substantial ABCG2 overexpression.
Furthermore, the use of TSA alone did not increase ABCG2 gene expres-
sion in any of the parental or ABCG2-overexpressing tumor cell lines
Figure 3. The effect of epigenetic modifying agents on the status of ABCG2 promoter methylation and consequent transcription in parental
cells and the correspondingMDRcells. QPCRanalysis of ABCG2 transcript in CCRF-CEM (A), IGROV1 (B) cells, and theirMDRsublinesCCRF-
CEM/SSZ2.5 (C) and IGROV1/T8 (D) thatwere treated for 72 hourswith 2 μMof the demethylating agent 5-Aza-dC, in the presence or absence
of 75ng/ml of theHDACi-TSA. To somesamples, 0.5μg/ml of the transcription inhibitorActDwas added in combinationwith the latter. abcg2
promoter methylation status was assessed using COBRA in parental CCRF-CEM and MDR CCRF-CEM/SSZ2.5 cells as well as CCRF-CEM
cells treatedwith 5-Aza-dC+ zebularine (E; seeMaterials andMethods for details). The corresponding ABCG2mRNA expression levelswere
assessed using QPCR (F); all QPCR results are expressed as fold of expression relative to the corresponding untreated or parental cells.
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(P > .24; Figure 3, A–D). To verify that restoration of ABCG2 gene
expression is due to transcriptional up-regulation rather than alterations
in ABCG2 mRNA stability, we used the transcription inhibitor Act D.
Concurrent addition of Act D to 5-Aza-dC– and TSA-treated tumor
cells resulted in the loss of ABCG2 gene expression in both parental
and MDR cells (Figure 3, A–D).
We further evaluated the ability of demethylating agents to confer drug
resistance on abcg2 promoter-methylated parental cell lines, thereby
mimicking the epigenetic events underlying the observed MDR pheno-
type of the corresponding sublines, using a 72-hour cytotoxicity assay
with known ABCG2 substrates. However, the demethylating agent
5-Aza-dC is unstable in cell culture conditions and is known to cause
a marked cellular toxicity under long-term exposure [26]. Hence, to
eliminate the component of cell toxicity while achieving steady-state de-
methylation, we used a combined demethylation protocol (see Mate-
rials and Methods) [41] with the stable and mild nucleoside analog
zebularine for a period of 30 days. Zebularine is a novel DNA methyla-
tion inhibitor that forms a covalent complex with DNMTs. Application
of this protocol to parental CCRF-CEMcells, which originally contained
ABCG2 promotermethylation, resulted in a greater than 20%demethyl-
ation of ABCG2 gene copies in the population (Figure 3E ) and in a con-
sequent 10-fold increase in ABCG2 transcript levels, relative to untreated
parental CCRF-CEMcells (Figure 3F ). Accordingly, a 72-hour cytotoxi-
city assay revealed a significant (P = .0006) three-fold increase in cellular
drug resistance of the zebularine-treated cells to MX, a well-established
ABCG2 transport substrate, relative to untreated cells (Table 2). This re-
sistance was completely reversed using the ABCG2-specific transport in-
hibitor FTC. However, despite the observed FTC-dependent five-fold
resistance of CCRF-CEM/SSZ2.5 cells to the ABCG2 transport sub-
strate SSZ, zebularine-treated cells retained parental cell sensitivity to this
drug, possibly because SSZ is a relatively low-affinity ABCG2 transport
substrate (Table 2) [40].
In Vitro Promoter Methylation Accounts for the Complete
Silencing of ABCG2 Promoter Activity
Despite the cumulative effect of 5-Aza-dC and zebularine on the
restoration of ABCG2 gene expression in parental cells harboring a
methylated ABCG2 promoter, the degree of ABCG2 overexpression
in the corresponding MDR sublines remained substantially higher,
with an additional 183- and 14-fold of ABCG2 overexpression in
IGROV1/T8 and CCRF-CEM/SSZ2.5, respectively. To preclude the
existence of additional mechanisms underlying ABCG2 overexpres-
sion in theseMDR cell lines, we explored the ability of in vitromethyla-
tion to account for the attenuation of ABCG2 transcription using a
luciferase reporter assay with the 1285/+362 ABCG2 promoter con-
struct in IGROV1 and IGROV1/T8 cells. This assay demonstrated
that in vitro methylation of the previously mentioned ABCG2 pro-
moter construct resulted in the complete loss of luciferase activity in both
IGROV1 and IGROV1/T8 cells (P < .004; Figure 4). These findings
indicate that ABCG2 promoter methylation mediates a robust gene
silencing capacity, regardless of the underlying transcriptional potential
of the cells.
ABCG2 Promoter Methylation Is Observed in T-ALL Cell
Lines and Some T-ALL Samples
Our current findings suggest that abcg2 promoter methylation is
an inherent characteristic of tumor cell lines from different tissue ori-
gins. We specifically find here that abcg2 promoter methylation ap-
pears to be present in several T-ALL cell lines including CCRF-CEM
and Jurkat cells (Figure 5). To expand the validity of our findings, the
status of ABCG2 promoter methylation was assessed using the COBRA
technique on genomic DNA from primary T cells and T-ALL lympho-
blasts obtained from peripheral blood of four healthy individuals and
four adult T-ALL patients at diagnosis, respectively. abcg2 promoter
methylation was not observed in any of the healthy blood samples; how-
ever, one of the T-ALL patients displayed approximately 50% methyla-
tion of the CpG island in the abcg2 promoter (Figure 5).
Anticancer Drug Exposure Induces a Dose-Dependent
Restoration of ABCG2 Gene Expression in Transcriptionally
Silenced Tumor Cell Lines within a Single Cell Cycle
The observed chemoresistance in IGROV1/T8, IGROV1/MX3, and
CCRF-CEM/SSZ2.5 cells may have emerged owing to the selection of
either a preexisting variant or a phenotype induced by the mutagenic
effect of the cytotoxic agent itself. Thus, to pinpoint the upstream mo-
lecular events that occur after drug exposure, dose- and time-dependent
Table 2. Summary of Growth Inhibition Studies on Parental CCRF-CEM, MDR CCRF-CEM/SSZ2.5 Subline, and 5-Aza-dC (AZA) + Zebularine (ZEB)–Treated CCRF-CEM Cells, on 72 Hours of
Exposure to Established ABCG2 Substrate Drugs in the Presence or Absence of the ABCG2 Inhibitor FTC.
Drug Cell Line
IC50
CCRF-CEM CCRF-CEM/SSZ2.5 CCRF-CEM/AZA + ZEB
−FTC +FTC −FTC +FTC −FTC +FTC
MX (nM) 18 ± 3 (1.0) 15 ± 5 (0.8) 172 ± 16 (9.5) 32 ± 7 (1.8) 55 ± 7 (3.0) 20 ± 4 (1.1)
SSZ (μM) 627 ± 47 (1.0) 733 ± 91 (1.2) 2860 ± 212 (4.6) 995 ± 83 (1.6) 687 ± 41 (1.1) 702 ± 88 (1.1)
IC50 was evaluated using a hemocytometer after trypan blue staining.
Figure 4. Effect of in vitromethylation on ABCG2 promoter activity.
Methylated and nonmethylated−1285/+362 ABCG2 promoter lucif-
erase reporter constructs were transiently transfected into parental
IGROV1 and MDR IGROV1/T8 cells and the relative luciferase ac-
tivity was determined. Results are expressed as the average (±SD)
luciferase-to-Renilla ratio of three experiments.
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exposures of the abcg2-methylated cell line CCRF-CEM to various
chemotherapeutics were assessed, and the consequent relative change
in ABCG2 transcript level was assessed byQPCR.We found that several
antitumor agents administered at clinically relevant doses induced a
marked increase in ABCG2 transcript levels, whereas DNR induced
the highest increase (55-fold) in ABCG2 transcript levels, other anthra-
cyclines tested including Dox andMX induced a 14- and 17-fold eleva-
tion of ABCG2 transcript levels, respectively (P < .002). This increase
in ABCG2 mRNA levels was observed within a defined concentration
range, in a dose-dependent manner (Figure 6A); cytotoxicity was evi-
dent at the relatively higher drug concentrations, thereby severely affect-
ing cellular viability and subsequently impairing ABCG2 overexpression
(Figure 6A). This drug-induced increase in ABCG2 mRNA was ob-
served as early as 12 hours after treatment, peaking at 24 hours and
diminishing gradually thereafter owing to a marked drug-induced toxic-
ity and subsequent cell death (Figure 6B). Drug-induced increase in
ABCG2 transcript levels, albeit at lower levels, was also observed when
using SSZ (P = .0048; Figure 6C). However, several antitumor agents
including the camptothecins topotecan and SN-38 as well as the anti-
mitotic agent paclitaxel (Taxol) failed to induce a significant change
in ABCG2 mRNA levels, when compared with untreated controls
(P > .06; Figure 6C ). The observed drug-induced increase in ABCG2
mRNA was maintained on the addition of the ABCG2-specific inhibi-
tor FTC but completely abolished by the addition of the transcriptional
inhibitor Act D (Figure 6C ). Comparable results, albeit at lower levels,
were achieved when treating the other abcg2-methylated Jurkat cell
line (P < .01; Figure 6D); however, drug treatment of the nonmethylated
K562 cell line failed to induce alterations in ABCG2 transcript levels
(P > .1; Figure 6D). Similar results were obtained when treating non-
methylated MCF7 and A549 cells with DNR (data not shown). Inter-
estingly, QPCR analysis of gene expression of several other genes in
CCRF-CEM cells revealed a differential pattern of drug-induced up-
regulation, which correlated with their promoter CpG methylation
status. Both pcft and mdr1 promoters, shown to be methylated in
CCRF-CEM cells, displayed a marked transcriptional up-regulation
under comparable drug exposure (P < .008; Figure 6E). However, the
MDR transporter ABCC1 (MRP1), which is highly expressed in these
cells [47], did not undergo transcriptional up-regulation under drug
exposure (Figure 6E). Similar results were observed for the ubiquitously
expressed genes—histone 3.3, β2-microglobulin, hypoxanthine-guanine
phosphoribosyltransferase (HGPRT ), and glucose-6-phosphate dehy-
drogenase (G6PD) transcripts in DNR-treated CCRF-CEM cells (data
not shown). Thus, drug-induced overexpression of ABCG2 and other
methylated genes occurs only in transcriptionally silenced tumor cell
lines through active transcriptional up-regulation. This process seems
to be independent of the transport function of ABCG2 (Figure 6C ).
Discussion
Anticancer drug resistance mediated by the overexpression of ABCG2
is an important modality of MDR in multiple tumor cell lines selected
with various chemotherapeutic agents [7]. Several mechanisms have
been previously described that facilitate transcriptional up-regulation
of ABCG2 in different MDR cell line models: 1) ABCG2 gene am-
plification, 2) chromosomal rearrangements, and 3) alternative 3′-
untranslated–mediated mRNA stability [48]. It has been recently
shown that the ABCG2 promoter undergoes CpG island methylation
in renal cell carcinoma lines, thereby resulting in epigenetic silencing
[33]. Thus, drug-induced epigenetic modulation of ABCG2 gene ex-
pression has gained increasing focus in a number of recent publications
[35,36]. Here, we show for the first time that ABCG2 promoter de-
methylation is a key mechanism underlying the reactivation of ABCG2
transcription and subsequent ABCG2-dependent MDR phenotype in
the T-ALL, drug-selected cell line CCRF-CEM/SSZ2.5 and the ovarian
carcinoma MDR cell lines IGROV1/T8 and IGROV1/MX3. Im-
portantly, our present results suggest that this mode of restoration of
ABCG2 gene expression in epigenetically silenced tumor cell lines
may be directly induced by chemotherapeutic drug exposure as early
as 12 hours after exposure, hence occurring within a single cell cycle.
To date, the most frequently occurring mechanism of ABCG2 over-
expression in MDR tumor cell lines is abcg2 gene amplification [49–
51]. Interestingly, MDR cells exhibiting this modality of up-regulation
were all derived from solid tumors of epithelial origin, thereby har-
boring distinct basal ABCG2 transcription. Accordingly, ABCG2 tran-
script levels in the carcinoma cell lines studied here were several orders
of magnitude higher than those observed in human leukemia CCRF-
CEM and ovarian carcinoma IGROV1 cells, harboring abcg2 pro-
moter methylation. This dramatic difference in basal ABCG2 gene
expression leads us to explore an alternative paradigm for the epigenetic
mode of up-regulation of ABCG2, emerging in drug-selected malig-
nant cells displaying poor basal levels of ABCG2 transcripts. We hy-
pothesized that the lack of basal transcription in these epigenetically
silenced tumor cell lines may impede their ability to undergo abcg2
Figure 5. Quantitative determination of abcg2 promoter methylation status in hematolymphoid cells. Genomic DNA was extracted from
peripheral blood T cells of healthy volunteers (top lane 1-4), peripheral blood lymphoblasts from adult T-ALL patients (middle lane 1-4), T-ALL
cell lines CCRF-CEM, JURKAT, and MOLT4 (bottom lane 1-3), and the erythroleukemia cell line K562. A 223-bp fragment (fragment B)
of bisulfite-converted genomic DNA from within the abcg2 promoter CpG island was PCR-amplified and subjected to COBRA (as de-
scribed above).
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gene amplification under drug-selective pressure, using two comple-
mentary mechanisms: 1) Heterochromatin-associated, increased ge-
nomic stability at the genomic ABCG2 locus. 2) Under drug-selective
pressure, the complete lack of ABCG2 function in these silenced cells
deprives them of a crucial MDR driving and protective force. Thus,
these silenced tumor cells may lack the crucial molecular tools facili-
tating drug-induced genomic amplification; as such, these cells must
rely on a different mode for ABCG2 up-regulation presumably occur-
ring at the early stages of drug exposure. Reactivation of transcription
in epigenetically silenced genes due to loss of promoter methylation
may meet this exact need. This is in accord with our current find-
ings: 1) chemotherapeutic drug–induced transcriptional up-regulation
of ABCG2 and other methylated genes occurs as early as 12 hours after
initial drug exposure, hence resulting in as much as 55-fold increased
ABCG2 transcript levels within a single cell cycle. This early up-
regulation of ABCG2 under drug exposure may provide the necessary
initial driving force for acquisition of the MDR phenotype under drug
selection, endogenously lacking in these ABCG2-silenced cells. 2) Pre-
vious analysis of the abcg2 promoter revealed multiple binding sites
for strong and constitutive transcriptional factors [43], which, on loss
of repression through demethylation, may readily restore promoter
binding, thereby resulting in the dramatic increase in ABCG2 over-
expression, ultimately leading to the MDR phenotype. The striking
(>700-fold) up-regulation of ABCG2 transcript due to the elimination
of CpG island promoter methylation in our drug-selected cells may
portray exactly this scenario. This is also corroborated in our ABCG2
Figure 6. The effect of short-term drug exposure on ABCG2 gene expression. CCRF-CEM cells were subjected to MX, Dox, and DNR in a
dose- (A) and time-dependent (B) manner. Cells were harvested, and relative abcg2 mRNA levels were assessed using QPCR. Furthermore,
the effect of functional inhibition of ABCG2 using the transport inhibitor FTC and transcriptional inhibition using Act D on drug-induced
ABCG2 gene expression in CCRF-CEM cells was assessed (C). Drug-induced ABCG2 expression was evaluated in abcg2 methylated and
nonmethylated cell lines Jurkat and K562, respectively (D). Drug-induced relative up-regulation of ABCG2 gene expression was expanded to
other known silenced and nonsilenced genes in CCRF-CEM cells (E). Drug concentration and incubation times were set at an optimal in-
duction capacity. QPCR expression levels are presented as fold expression relative to untreated cells.
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promoter activity assay displaying equal and significant transcriptional
activity in both parental (silenced) cells and their paired MDR sublines.
3) The robust silencing produced by our in vitromethylation assay on the
previously reported ABCG2’s proximal promoter [43], in both IGROV1
and IGROV1/T8 cell lines, demonstrates its ABCG2-silencing capacity,
which, on demethylation, unleashes the observed high transcriptional
potential of this MDR gene. 4) The marked difference in basal ABCG2
expression between promoter methylated and nonmethylated tumor cell
lines revealed differential characteristics of ABCG2 up-regulation in their
correspondingMDR sublines. Accordingly, genomically amplifiedMDR
carcinoma sublines displayed the absolute highest ABCG2overexpression
levels, consistent with their degree of abcg2 gene amplification. In
contrast, the demethylated MDR sublines displayed only moderate
ABCG2 expression while producing themost prominent relative increase
in ABCG2 transcript levels when compared with their parental cells.
Thus, as opposed to the linear transcriptional effect of genomic amplifi-
cation, alterations in the status of promotermethylationmay dramatically
modulate ABCG2 gene expression in an “all-or-none” fashion, thereby
conferring sufficient levels of MDR under drug-selective pressure.
It is noteworthy that neither treatment with bona fide epigenetics
modifiers including 5-Aza-dC and TSA nor treatment with various
antitumor agents, all of which produced a marked induction of methyl-
ated ABCG2 transcription, resulted in a noticeable increase in ABCG2
protein levels or drug efflux function, as assessed byWestern blot analy-
sis and flow cytometry–based chromophore drug accumulation assay
(data not shown). This may be explained by the extremely low basal
levels of ABCG2 mRNA in methylated parental cells, hence limiting
the ability to detect quantitative changes in protein levels. Although the
relative drug-induced up-regulation is remarkable (up to 55-fold), the
absolute levels of ABCG2 transcript in these drug-treated cells are
more than an order of magnitude lower than ABCG2 expression in
various parental cell lines such as MCF7 and A549 (compare relative
ABCG2 mRNA levels in Figures 1 to 3, A and F ). The latter parental
cells display only low ABCG2 protein levels and, accordingly, barely
detectable efflux function [37]. Nevertheless, although the absolute
drug-induced up-regulation of ABCG2 may seem extremely low, our
results reveal a significant three-fold ABCG2-mediated resistance to the
anticancer agent MX (Table 2). Thus, these results demonstrate the
ABCG2-dependent chemoprotective function achieved from levels as
low as 10-fold up-regulation of ABCG2mRNA produced by treatment
with demethylating agents (Figure 3F). ABCG2 expression and func-
tion in the drug-selected sublines CCRF-CEM/SSZ2.5 and IGROV1/
Figure 7. Schematic representation of the putative dynamics of abcg2 promoter methylation in tumor progression and under anticancer
drug treatment.
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T8 are indeed markedly high (i.e., corresponding to >200- and 700-fold
mRNA overexpression, respectively). However, this is a result of the
prolonged multistep drug selection protocol used to achieve this MDR
phenotype. Thus, although our results display only low levels of ABCG2-
mediated resistance, they may bear important implications for the early
molecular events and dynamics of induction of MDR gene expression,
in particular the dynamics of restoration of silent MDR gene expression
under cytotoxic stress with chemotherapeutic agents. These early quan-
titative alterations in ABCG2 gene expression are relatively small and are
therefore detectable only using very high sensitivity analyses such as real-
time PCR. However, these early changes can be the very beginning of
the multistage process that presumably leads to the ultimate ABCG2
overexpression–dependent MDR phenotype.
The aberrant methylation of CpG islands is a hallmark of cancer,
leading to the epigenetic silencing of genes that normally function in
all different aspects of suppression of malignant transformation, tumor
cell growth, and metastasis [21]. This process is considered to occur
owing to the deregulation of DNMT activity [23], thereby leading
to the stochastic methylation of dense CpG islands throughout the
cancer cell genome. Moreover, CpG hypermethylation is considerably
augmented during the process of tumor cell line establishment by yet
unknown mechanisms [52]. Thus, the random silencing of ABCG2
gene expression through CpG island promoter methylation may be a
common event in cancer cell lines and possibly human malignancies.
Our results focused on several different cell lines harboring ABCG2
promoter methylation. Interestingly, our ABCG2 methylation analysis
revealed that promoter methylation seems to be more common within
T-ALL–derived cell lines, when compared with the array of solid tumor
cell lines tested. This observation is in accord with the physiological tis-
sue distribution and expression levels of ABCG2. Active transcription
has been reported to repress de novo CpG methylation through tran-
scription factor protection [53]. Conversely, histone modifications such
as deacetylation promote DNA condensation and contribute to DNA
methylation [18]. Therefore, relatively low levels of ABCG2 transcrip-
tion observed in primary T-cell lineage [54] may reflect a general state
of tightly packed DNA at this genomic locus, thereby contributing to
the susceptibility of the ABCG2 promoter to undergo hypermethylation
during malignant transformation. Indeed, ABCG2 promoter methyla-
tion was observed in T-ALL clinical samples. This preliminary observa-
tion warrants a large cohort study to reliably determine the prevalence
and possible therapeutic implications of ABCG2 promoter methylation
in T-ALL and other leukemia. A model summarizing the putative dy-
namics of ABCG2 promoter methylation in tumor progression and
under anticancer drug exposure is depicted in Figure 7.
It has been previously suggested that the therapeutic use of demethyl-
ating agents for the treatment of hematological malignancies may serve
as a double-edged sword which, while inducing the reexpression of the
necessary silenced tumor-suppressor genes, might also provoke the
reexpression of proto-oncogenes [55]. In light of our current findings,
ABCG2 may also be reexpressed under combination chemotherapeutic
regimens, which may include demethylating agents and ABCG2 trans-
port substrates; this could ultimately lead to the generation of highly
MDR clones in the clinical setting. Also, the use of methylated oligo-
nucleotides has been reported to specifically target and induce tran-
scriptional silencing of methylation-sensitive genes in both in vitro and
in vivo models, through complementary association to the target gene
followed by recruitment of DNMTmachinery [56]. It is likely that the
strong susceptibility of the ABCG2 gene to silencing through promoter
methylation may render it an excellent candidate for in vivo methyl-
ated oligonucleotide treatment in MDR tumor models in conjunction
with chemotherapy and possibly subsequent to treatment with de-
methylating agents.
Acknowledgments
The authors thank Irit Avivi from the Department of Hematology,
Rambam Medical Center, Haifa, Israel, for generously providing the
primary T-ALL specimens. The authors also thank Hila Novak for
her help with the isolation of primary T-cells.
References
[1] Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, and GottesmanMM (2006).
Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219–234.
[2] Borst P and Elferink RO (2002). Mammalian ABC transporters in health and
disease. Annu Rev Biochem 71, 537–592.
[3] Dean M, Rzhetsky A, and Allikmets R (2001). The human ATP-binding cassette
(ABC) transporter superfamily. Genome Res 11, 1156–1166.
[4] Borst P, Evers R, Kool M, and Wijnholds J (2000). A family of drug transporters:
the multidrug resistance–associated proteins. J Natl Cancer Inst 92, 1295–1302.
[5] Deeley RG, Westlake C, and Cole SP (2006). Transmembrane transport of
endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance
proteins. Physiol Rev 86, 849–899.
[6] Litman T, Druley TE, Stein WD, and Bates SE (2001). From MDR to MXR:
new understanding of multidrug resistance systems, their properties and clinical
significance. Cell Mol Life Sci 58, 931–959.
[7] Polgar O, Robey RW, and Bates SE (2008). ABCG2: structure, function and
role in drug response. Expert Opin Drug Metab Toxicol 4, 1–15.
[8] Sarkadi B, Ozvegy-Laczka C, Nemet K, and Varadi A (2004). ABCG2 — a
transporter for all seasons. FEBS Lett 567, 116–120.
[9] Colabufo NA, Berardi F, Contino M, Niso M, and Perrone R (2009). ABC pumps
and their role in active drug transport. Curr Top Med Chem 9, 119–129.
[10] Sharom FJ (2008). ABC multidrug transporters: structure, function and role in
chemoresistance. Pharmacogenomics 9, 105–127.
[11] Sarkadi B, Homolya L, Szakacs G, and Varadi A (2006). Human multidrug resis-
tance ABCB and ABCG transporters: participation in a chemoimmunity defense
system. Physiol Rev 86, 1179–1236.
[12] Bernstein BE, Meissner A, and Lander ES (2007). The mammalian epigenome.
Cell 128, 669–681.
[13] Bird A (2002). DNA methylation patterns and epigenetic memory. Genes Dev
16, 6–21.
[14] Gonen N, Bram EE, and Assaraf YG (2008). PCFT/SLC46A1 promoter methyla-
tion and restoration of gene expression in human leukemia cells. Biochem Biophys
Res Commun 376, 787–792.
[15] Campanero MR, Armstrong MI, and Flemington EK (2000). CpG methylation
as a mechanism for the regulation of E2F activity. Proc Natl Acad Sci USA 97,
6481–6486.
[16] Iguchi-Ariga SM and Schaffner W (1989). CpG methylation of the cAMP-
responsive enhancer/promoter sequence TGACGTCA abolishes specific factor
binding as well as transcriptional activation. Genes Dev 3, 612–619.
[17] Kudo S (1998). Methyl-CpG–binding protein MeCP2 represses Sp1-activated
transcription of the human leukosialin gene when the promoter is methylated.
Mol Cell Biol 18, 5492–5499.
[18] Bogdanovic O and Veenstra GJ (2009). DNAmethylation and methyl-CpG bind-
ing proteins: developmental requirements and function. Chromosoma 118 (5),
549–565 [Epub 2009 June 9].
[19] Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, and
Bird A (1998). Transcriptional repression by the methyl-CpG–binding protein
MeCP2 involves a histone deacetylase complex. Nature 393, 386–389.
[20] Esteller M and Herman JG (2002). Cancer as an epigenetic disease: DNA methyla-
tion and chromatin alterations in human tumours. J Pathol 196, 1–7.
[21] Plass C and Smiraglia DJ (2006). Genome-wide analysis of DNA methylation
changes in human malignancies. Curr Top Microbiol Immunol 310, 179–198.
[22] Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC,
and Motamed K (2009). Aberrant promoter methylation of SPARC in ovarian
cancer. Neoplasia 11, 126–135.
[23] Ellis L, Atadja PW, and Johnstone RW (2009). Epigenetics in cancer: targeting
chromatin modifications. Mol Cancer Ther 8, 1409–1420.
Neoplasia Vol. 11, No. 12, 2009 Drug-induced ABCG2 Promoter Demethylation Bram et al. 1369
[24] Claus R, Almstedt M, and Lubbert M (2005). Epigenetic treatment of hemato-
poietic malignancies: in vivo targets of demethylating agents. Semin Oncol 32,
511–520.
[25] Issa JP (2007). DNA methylation as a therapeutic target in cancer. Clin Cancer
Res 13, 1634–1637.
[26] Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ, and
Kim TY (2007). Potential advantages of DNA methyltransferase 1 (DNMT1)–
targeted inhibition for cancer therapy. J Mol Med 85, 1137–1148.
[27] Assaraf YG, Molina A, and Schimke RT (1989). Sequential amplification of
dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary
cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate.
J Biol Chem 264, 18326–18334.
[28] Borellini F, Aquino A, Josephs SF, and Glazer RI (1990). Increased expression
and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant
HL-60 leukemia cells. Mol Cell Biol 10, 5541–5547.
[29] Borgnia MJ, Eytan GD, and Assaraf YG (1996). Competition of hydrophobic
peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein
pharmacophore as revealed by its ATPase activity. J Biol Chem 271, 3163–3171.
[30] El-Osta A, Kantharidis P, Zalcberg JR, and Wolffe AP (2002). Precipitous release
of methyl-CpG binding protein 2 and histone deacetylase 1 from the methyl-
ated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 22,
1844–1857.
[31] Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M, and
Wada M (1999). Association of 5′CpG demethylation and altered chromatin struc-
ture in the promoter region with transcriptional activation of themultidrug resistance
1 gene in human cancer cells. Eur J Biochem 262, 924–932.
[32] Baker EK, Johnstone RW, Zalcberg JR, and El-Osta A (2005). Epigenetic
changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24,
8061–8075.
[33] To KK, Zhan Z, and Bates SE (2006). Aberrant promoter methylation of the
ABCG2 gene in renal carcinoma. Mol Cell Biol 26, 8572–8585.
[34] Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L,
Munster P, Schell MJ, DaltonWS, and Sullivan DM (2006). ABCG2 expression,
function, and promoter methylation in human multiple myeloma. Blood 108,
3881–3889.
[35] Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu
CP, Varticovski L, Bates SE, Caplen NJ, et al. (2008). Single-step doxorubicin-
selected cancer cells overexpress the ABCG2 drug transporter through epigenetic
changes. Br J Cancer 98, 1515–1524.
[36] To KK, Polgar O, Huff LM, Morisaki K, and Bates SE (2008). Histone modifica-
tions at the ABCG2 promoter following treatment with histone deacetylase inhib-
itor mirror those in multidrug-resistant cells. Mol Cancer Res 6, 151–164.
[37] Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, and Assaraf YG
(2007). C421 allele-specific ABCG2 gene amplification confers resistance to the
antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol
74, 41–53.
[38] Ifergan I, Scheffer GL, and Assaraf YG (2005). Novel extracellular vesicles me-
diate an ABCG2-dependent anticancer drug sequestration and resistance. Cancer
Res 65, 10952–10958.
[39] Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC,
Ruevekamp-Helmers MC, Floot BG, and Schellens JH (1999). Overexpression
of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Cancer Res 59, 4559–4563.
[40] van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R,
Kathmann I, Schalkwijk CG, Scheffer GL, Scheper RJ, and Jansen G (2004).
Development of sulfasalazine resistance in human T cells induces expression of
the multidrug resistance transporter ABCG2 (BCRP) and augmented production
of TNFα. Ann Rheum Dis 63, 138–143.
[41] Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez
VE, and Jones PA (2004). Continuous zebularine treatment effectively sustains
demethylation in human bladder cancer cells. Mol Cell Biol 24, 1270–1278.
[42] Lee TB, Park JH, Min YD, Kim KJ, and Choi CH (2008). Epigenetic mechanisms
involved in differential MDR1 mRNA expression between gastric and colon cancer
cell lines and rationales for clinical chemotherapy. BMC Gastroenterol 8, 33.
[43] Bailey-Dell KJ, Hassel B, Doyle LA, and Ross DD (2001). Promoter characteriza-
tion and genomic organization of the human breast cancer resistance protein (ATP-
binding cassette transporter G2) gene. Biochim Biophys Acta 1520, 234–241.
[44] Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK,
Burnett AK, Chopra R, Wiernik PH, Foroni L, et al. (2008). In adults with
standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from
a matched sibling allogeneic transplantation in first complete remission, and
an autologous transplantation is less effective than conventional consolidation/
maintenance chemotherapy in all patients: final results of the International ALL
Trial (MRC UKALL XII/ECOG E2993). Blood 111, 1827–1833.
[45] Liu H, Zhou Y, Boggs SE, Belinsky SA, and Liu J (2007). Cigarette smoke in-
duces demethylation of prometastatic oncogene synuclein-gamma in lung cancer
cells by downregulation of DNMT3B. Oncogene 26, 5900–5910.
[46] Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G,
Parkin JD, and Zalcberg JR (1997). Altered methylation of the human MDR1
promoter is associated with acquired multidrug resistance. Clin Cancer Res 3,
2025–2032.
[47] Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I,
Dijkmans BA, Peters GJ, and Jansen G (2003). Loss of multidrug resistance pro-
tein 1 expression and folate efflux activity results in a highly concentrative folate
transport in human leukemia cells. J Biol Chem 278, 6680–6686.
[48] To KK, Zhan Z, Litman T, and Bates SE (2008). Regulation of ABCG2 expres-
sion at the 3′ untranslated region of its mRNA through modulation of transcript
stability and protein translation by a putative microRNA in the S1 colon cancer cell
line. Mol Cell Biol 28, 5147–5161.
[49] Allen JD, Brinkhuis RF, Wijnholds J, and Schinkel AH (1999). The mouse Bcrp1/
Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance
to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59, 4237–4241.
[50] Knutsen T, Rao VK, Ried T, Mickley L, Schneider E, Miyake K, Ghadimi BM,
Padilla-Nash H, Pack S, Greenberger L, et al. (2000). Amplification of 4q21-q22
and the MXR gene in independently derived mitoxantrone-resistant cell lines.
Genes Chromosomes Cancer 27, 110–116.
[51] Rao VK, Wangsa D, Robey RW, Huff L, Honjo Y, Hung J, Knutsen T, Ried T,
and Bates SE (2005). Characterization of ABCG2 gene amplification manifesting
as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma
cells. Cancer Genet Cytogenet 160, 126–133.
[52] Antequera F, Boyes J, and Bird A (1990). High levels of de novomethylation and
altered chromatin structure at CpG islands in cell lines. Cell 62, 503–514.
[53] Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, Temper V,
Razin A, and Cedar H (1994). Sp1 elements protect a CpG island from de novo
methylation. Nature 371, 435–438.
[54] Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates
SE, Scheffer GL, Scheper RJ, Vellenga E, and de Vries EG (2003). The role of
breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res
9, 5171–5177.
[55] Cui W and Wang L-H (2008). DNA methylation: a two-edged sword as a target
for anti-cancer drugs. Biosci Hypotheses 1, 334–335.
[56] Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q,
Li T, et al. (2003). A methylated oligonucleotide inhibits IGF2 expression and
enhances survival in a model of hepatocellular carcinoma. J Clin Invest 111,
265–273.
[57] OguraM, Takatori T, Sugimoto Y, and Tsuruo T (1991). Identification and charac-
terization of three DNA-binding proteins on the promoter of the human MDR1
gene in drug-sensitive and -resistant cells. Jpn J Cancer Res 82, 1151–1159.
[58] Shinoda C, Maruyama M, Fujishita T, Dohkan J, Oda H, Shinoda K, Yamada T,
Miyabayashi K, Hayashi R, Kawagishi Y, et al. (2005). Doxorubicin induces expres-
sion of multidrug resistance–associated protein 1 in human small cell lung cancer
cell lines by the c-jun N-terminal kinase pathway. Int J Cancer 117, 21–31.
1370 Drug-induced ABCG2 Promoter Demethylation Bram et al. Neoplasia Vol. 11, No. 12, 2009
Supplementary Data
Material and Methods
Determination of abcg2 gene amplification using quantitative
genomic PCR. Quantification of abcg2 gene copy number in
MDR sublines relative to parental counterparts was performed. Serial
dilutions of template DNA in a PCR were compared using the pre-
viously described settings, primers, and internal controls [37].
Transient transfections with pGL3-abcg2 promoter expression vectors
and luciferase reporter gene assay. For the luciferase reporter assay,
IGROV1 and IGROV1/T8 cells were grown in 24-mm dishes (3 ×
104 cells per well) for 24 hours, after which cells were transiently
cotransfected with pGL3-abcg2 constructs (generously provided by
Dr. Douglas D. Ross) [43], including the pGL3-Basic empty vector,
along with the extensively used pROL control plasmid (Renilla lucif-
erase) using the jetPEI transfection reagent (Polyplus-transfection) ac-
cording to the instructions of the manufacturer. Twenty-four hours
after transient transfection, cells were harvested and tested for luciferase
and Renilla activities using the Dual-Luciferase Reporter Assay System
(Promega) as described in the manufacturer’s protocol. Results pre-
sented were obtained from at least three independent experiments per-
formed in duplicate cultures.
Result
Lack of abcg2 gene amplification in IGROV1- and CCRF-CEM–
derived MDR cell lines. Previous studies have shown that the
marked overexpression of ABCG2 in drug selected tumor cell lines
of different tissue origin is frequently due to abcg2 gene amplification
[49–51]. Consistently, approximately 5-, 7-, and 16-fold abcg2 gene
amplification was found in MCF7/FLV1000, MCF7/MRi and A549/
K1.5 cells, respectively (Figure W1) [37]. In contrast, semiquantitative
genomic PCR analysis revealed that the abcg2 gene was not amplified
in the ABCG2-overexpressing IGROV1/T8, IGROV1/MX3, and
CCRF-CEM/SSZ2.5 cells (Figure W1). Thus, the molecular mecha-
nism underlying ABCG2 overexpression in these MDR cell lines is
not genomic amplification of the abcg2 gene.
Transacting factors do not contribute to up-regulation of ABCG2
in IGROV1-derived MDR cell lines. To date, no molecular
mechanism of transcriptional transactivation has yet been associated
with up-regulation of ABCG2 in drug-selected cell lines. However, this
is not the case with the extensively studied MDR transporters ABCB1
(Pgp, MDR1) and ABCC1 (MRP1), which exhibit various mecha-
nisms of transactivation in drug selected tumor cell lines [28,57,58].
We hence investigated the possible involvement of transacting factors
in this up-regulation of ABCG2 in the nongenomically amplified
MDR cell line IGROV1/T8. To this end, a luciferase reporter assay
was used on transient transfection in both parental IGROV1 and
MDR IGROV1/T8 cells, using the previously described [43] −1285/
+362, −312/+362, and −115/+362 consecutive ABCG2 promoter
deletion constructs (Figure W2). In contrast to the transcriptional up-
regulation of ABCG2 in IGROV1/T8 cells, all ABCG2 promoter
constructs demonstrated slightly lower activity in IGROV1/T8 cells
than their activity in parental IGROV1 cells (Figure W2). Yet, the pos-
itive control construct harboring activating transcription factor main-
tained parental ABCG2 expression levels. Thus, changes in transacting
factors do not seem to contribute to ABCG2 up-regulation in IGROV1/
T8 cells.
Figure W1. Determination of abcg2 gene copy number in paired
parental and MDR cells by genomic QPCR analysis. Genomic DNA
was extracted from cells and the abcg2 gene copy number was
determined using QPCR with five serial dilutions of the template ge-
nomic DNA, inmatched parental IGROV1withMDR IGROV1/MX3 (A)
or IGROV1/T8 (B), matched parental CCRF-CEM cells and their MDR
subline CCRF-CEM/SSZ2.5 (C), or matched parental MCF7 and MDR
sublinesMCF7/MR (D) orMCF7/FLV1000 (E). Equal template amount
was assessed using genomic β-actin as an internal control.
Figure W2. Comparison of ABCG2 promoter activity in parental
IGROV1 cells and their MDR subline IGROV1/T8. A luciferase reporter
vector harboring the −1285, −312, or −115 consecutive fragments
of the ABCG2 promoter was transfected into IGROV1 and IGROV1/
T8 cells. The activating transcription factor promoter construct was
used as a control. Results represent the activity of luciferase/Renilla
ratio of the constructs in the MDR IGROV1/T8 cells as a percent of
the luciferase/Renilla ratio activity in their parental IGROV1 cells. Re-
sults are the means of at least three independent experiments per-
formed in duplicates ± SD.
